Genentech’s Rituxin Secures FDA Pediatric Indications for B-Cell Cancers

Genentech’s Rituxin (rituximab) has received several FDA approvals for use along with chemotherapy for treatment of four B-cell cancers in pediatric patients.

The cancers consist of CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma or mature B-cell acute leukemia.

The approvals were supported by positive survival data from an open-label global study evaluating Rituxin in patients with CD20-positive previously untreated, advanced stage forms of the cancers.